Transdermal formulations of deprenyl: Guinea pig and pig models

J. Gaal, Gy Szebeni, G. Szekacs, E. Fejer, O. Wagner, I. Szatmari, K. Magyar, M. Mezei

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The efficacy of many drugs relies on their presence at the site of action over a period of time. The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications. These problems may be solved using transdermal delivery systems. Transdermal systems are aimed for local, or systemic action. In the letter case controlling the rate of delivery or modulating the distribution in the organism. The selection of an adequate biological method of evaluating a new transdermal formulation is a critical point of the development. The in vitro methods can help in the characterization of the different formulas, but without an in vivo disposition study they cannot give relevant information about the expectable therapeutic behavior. We adapted and improved an in vivo test system for the evaluation of new transdermal particulate systems (patches) and liposomes containing deprenyl selegiline as active ingredient. The in vivo evaluation system consists of two steps: 1. Full biodisposition study on guinea pig, using isotope labeled selegiline. 2. Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods. Specific examples of these studies and experimental technology are presented.

Original languageEnglish
Pages (from-to)143-166
Number of pages24
JournalNeurobiology
Volume8
Issue number2
Publication statusPublished - 2000

Fingerprint

Selegiline
Guinea Pigs
Swine
Dosage Forms
Sus scrofa
Poisons
Liposomes
Isotopes
Biological Availability
Technology
Pharmaceutical Preparations
Therapeutics

Keywords

  • Deprenyl
  • MAO
  • Pig
  • Transdermal application

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gaal, J., Szebeni, G., Szekacs, G., Fejer, E., Wagner, O., Szatmari, I., ... Mezei, M. (2000). Transdermal formulations of deprenyl: Guinea pig and pig models. Neurobiology, 8(2), 143-166.

Transdermal formulations of deprenyl : Guinea pig and pig models. / Gaal, J.; Szebeni, Gy; Szekacs, G.; Fejer, E.; Wagner, O.; Szatmari, I.; Magyar, K.; Mezei, M.

In: Neurobiology, Vol. 8, No. 2, 2000, p. 143-166.

Research output: Contribution to journalArticle

Gaal, J, Szebeni, G, Szekacs, G, Fejer, E, Wagner, O, Szatmari, I, Magyar, K & Mezei, M 2000, 'Transdermal formulations of deprenyl: Guinea pig and pig models', Neurobiology, vol. 8, no. 2, pp. 143-166.
Gaal J, Szebeni G, Szekacs G, Fejer E, Wagner O, Szatmari I et al. Transdermal formulations of deprenyl: Guinea pig and pig models. Neurobiology. 2000;8(2):143-166.
Gaal, J. ; Szebeni, Gy ; Szekacs, G. ; Fejer, E. ; Wagner, O. ; Szatmari, I. ; Magyar, K. ; Mezei, M. / Transdermal formulations of deprenyl : Guinea pig and pig models. In: Neurobiology. 2000 ; Vol. 8, No. 2. pp. 143-166.
@article{75fcafed1e244c78b4bdaad410e350b4,
title = "Transdermal formulations of deprenyl: Guinea pig and pig models",
abstract = "The efficacy of many drugs relies on their presence at the site of action over a period of time. The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications. These problems may be solved using transdermal delivery systems. Transdermal systems are aimed for local, or systemic action. In the letter case controlling the rate of delivery or modulating the distribution in the organism. The selection of an adequate biological method of evaluating a new transdermal formulation is a critical point of the development. The in vitro methods can help in the characterization of the different formulas, but without an in vivo disposition study they cannot give relevant information about the expectable therapeutic behavior. We adapted and improved an in vivo test system for the evaluation of new transdermal particulate systems (patches) and liposomes containing deprenyl selegiline as active ingredient. The in vivo evaluation system consists of two steps: 1. Full biodisposition study on guinea pig, using isotope labeled selegiline. 2. Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods. Specific examples of these studies and experimental technology are presented.",
keywords = "Deprenyl, MAO, Pig, Transdermal application",
author = "J. Gaal and Gy Szebeni and G. Szekacs and E. Fejer and O. Wagner and I. Szatmari and K. Magyar and M. Mezei",
year = "2000",
language = "English",
volume = "8",
pages = "143--166",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "2",

}

TY - JOUR

T1 - Transdermal formulations of deprenyl

T2 - Guinea pig and pig models

AU - Gaal, J.

AU - Szebeni, Gy

AU - Szekacs, G.

AU - Fejer, E.

AU - Wagner, O.

AU - Szatmari, I.

AU - Magyar, K.

AU - Mezei, M.

PY - 2000

Y1 - 2000

N2 - The efficacy of many drugs relies on their presence at the site of action over a period of time. The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications. These problems may be solved using transdermal delivery systems. Transdermal systems are aimed for local, or systemic action. In the letter case controlling the rate of delivery or modulating the distribution in the organism. The selection of an adequate biological method of evaluating a new transdermal formulation is a critical point of the development. The in vitro methods can help in the characterization of the different formulas, but without an in vivo disposition study they cannot give relevant information about the expectable therapeutic behavior. We adapted and improved an in vivo test system for the evaluation of new transdermal particulate systems (patches) and liposomes containing deprenyl selegiline as active ingredient. The in vivo evaluation system consists of two steps: 1. Full biodisposition study on guinea pig, using isotope labeled selegiline. 2. Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods. Specific examples of these studies and experimental technology are presented.

AB - The efficacy of many drugs relies on their presence at the site of action over a period of time. The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications. These problems may be solved using transdermal delivery systems. Transdermal systems are aimed for local, or systemic action. In the letter case controlling the rate of delivery or modulating the distribution in the organism. The selection of an adequate biological method of evaluating a new transdermal formulation is a critical point of the development. The in vitro methods can help in the characterization of the different formulas, but without an in vivo disposition study they cannot give relevant information about the expectable therapeutic behavior. We adapted and improved an in vivo test system for the evaluation of new transdermal particulate systems (patches) and liposomes containing deprenyl selegiline as active ingredient. The in vivo evaluation system consists of two steps: 1. Full biodisposition study on guinea pig, using isotope labeled selegiline. 2. Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods. Specific examples of these studies and experimental technology are presented.

KW - Deprenyl

KW - MAO

KW - Pig

KW - Transdermal application

UR - http://www.scopus.com/inward/record.url?scp=0033774189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033774189&partnerID=8YFLogxK

M3 - Article

C2 - 11061212

AN - SCOPUS:0033774189

VL - 8

SP - 143

EP - 166

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 2

ER -